Last reviewed · How we verify
Beijing hypotensive No.0
Beijing hypotensive No.0 is an antihypertensive agent that reduces blood pressure through mechanisms typical of traditional Chinese medicine formulations or conventional antihypertensive pathways.
Beijing hypotensive No.0 is an antihypertensive agent that reduces blood pressure through mechanisms typical of traditional Chinese medicine formulations or conventional antihypertensive pathways. Used for Hypertension.
At a glance
| Generic name | Beijing hypotensive No.0 |
|---|---|
| Also known as | compound hypotensive tablet |
| Sponsor | West China Hospital |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This marketed drug from West China Hospital is indicated for hypertension management. Without access to detailed pharmacological documentation, the precise molecular mechanism—whether it acts as a vasodilator, sympatholytic agent, or through other pathways—cannot be definitively specified. The drug appears to be a formulation developed in China with established clinical use.
Approved indications
- Hypertension
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beijing hypotensive No.0 CI brief — competitive landscape report
- Beijing hypotensive No.0 updates RSS · CI watch RSS
- West China Hospital portfolio CI